Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 4, 2011, Pages 541-549

  Yang, Feng ^a   Jin, Chen ^a   Jiang, Yong Jian ^a   Li, Ji ^a   Di, Yang ^a   Fu, De Liang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

antiangiogenesis; cancer; hypertension; proteinuria; sFlt 1; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; NEUROPILIN 1; NEUROPILIN 2; PLACENTAL GROWTH FACTOR; SOLUBLE VASCULOTROPIN RECEPTOR 1; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; FIBROSARCOMA; GLIOBLASTOMA; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHANGIOGENESIS; MITOGENESIS; MULTIPLE MYELOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEINURIA; RECTUM CANCER; REVIEW; STOMACH CANCER; TONGUE CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79955105059     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.171     Document Type: Review

References (68)

1. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006). (Pubitemid 43108832)
2. Wu FTH, Stefanini MO, Mac Gabhann F et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J. Cell. Mol. Med. 14(3), 528-552 (2010).
3. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. 24(9), 1329-1331 (2006). (Pubitemid 46621994)
4. Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6(6), 327-338 (2009).
5. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12(12), 1443-1455 (2007).
6. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49(2), 186-193 (2007). (Pubitemid 46178407)
7. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354(9), 980-982; discussion 980-982 (2006).
8. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354(9), 980-982; discussion 980-982 (2006).
9. Bose D, Meric-Bernstam F, Hofstetter W et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 11(4), 373-382 (2010).
10. Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol. 10(2), 157-163 (2009).
11. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358(11), 1129-1136 (2008). (Pubitemid 351398487)
12. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9(2), 117-123 (2008).
13. Rini BI. Quantifying hypertension in patients with cancer treated with sorafenib. Lancet Oncol. 9(2), 86-87 (2008). (Pubitemid 351150123)
14. Beevers G, Lip GY, O'Brien E. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques. BMJ 322(7292), 981-985 (2001).
15. Chang JJ, Rabinowitz D, Shea S. Sources of variability in blood pressure measurement using the Dinamap PRO 100 automated oscillometric device. Am. J. Epidemiol. 158(12), 1218-1226 (2003). (Pubitemid 37548792)
16. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24(9), 1363-1369 (2006). (Pubitemid 46621999)
17. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 358(1), 95-97 (2008).
18. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr. Hypertens. Rep. 9(4), 320-328 (2007). (Pubitemid 47377031)
19. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303).J. Clin. Oncol. 28(22), 3617-3622 (2010).
20. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27(13), 2231-2237 (2009).
21. Chaplain MA, McDougall SR, Anderson AR. Mathematical modeling of tumor-induced angiogenesis. Annu. Rev. Biomed. Eng. 8, 233-257 (2006). (Pubitemid 44314817)
22. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9(4), 225-230; discussion 231 (2006).
23. Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5(4), 519-524 (1990).
24. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA 90(22), 10705-10709 (1993). (Pubitemid 23347111)
25. Helske S, Vuorela P, Carpen O et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol. Hum. Reprod. 7(2), 205-210 (2001). (Pubitemid 32148349)
26. Thomas CP, Andrews JI, Liu KZ. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J. 21(14), 3885-3895 (2007). (Pubitemid 350232346)
27. Sela S, Itin A, Natanson-Yaron S et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102(12), 1566-1574 (2008).
28. Heydarian M, McCaffrey T, Florea L et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30(3), 250-255 (2009).
29. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672-683 (2004). (Pubitemid 38364626)
30. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355(10), 992-1005 (2006). (Pubitemid 44343543)
31. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5), 649-658 (2003). (Pubitemid 36278583)
32. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278(15), 12605-12608 (2003). (Pubitemid 36800018)
33. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet 371(9630), 2101-2108 (2008).
34. Rini BI SJ, Fruehauf JP, Cohen EE et al. Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736).J. Clin. Oncol. 26(15S ), 3543 (2008).
35. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008).
36. Yamaguchi T, Bando H, Mori T et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci. 98(3), 405-410 (2007). (Pubitemid 46195613)
37. Toi M, Bando H, Ogawa T et al. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer 98(1), 14-18 (2002). (Pubitemid 34113411)
38. Lamszus K, Ulbricht U, Matschke J et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin. Cancer Res. 9(4), 1399-1405 (2003). (Pubitemid 36418393)
39. Hu Q, Dey AL, Yang Y et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 100(9), 1884-1891 (2004). (Pubitemid 38529566)
40. Bando H, Weich HA, Brokelmann M et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Brit. J. Cancer 92(3), 553-561 (2005). (Pubitemid 40395537)
41. Nagaoka S, Yoshida T, Akiyoshi J et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol. Rep. 23(6), 1647-1654 (2010).
42. Chang YT, Chang MC, Wei SC et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37(2), 145-150 (2008).
43. Aref S, El Sherbiny M, Goda T et al. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology 10(2), 131-134 (2005). (Pubitemid 41800786)
44. Kim WJ, Yockman JW, Jeong JH et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J. Control. Release 114(3), 381-388 (2006). (Pubitemid 44310812)
45. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 14(5), 488-498 (2007). (Pubitemid 46588197)
46. Takayama K, Ueno H, Nakanishi Y et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 60(8), 2169-2177 (2000). (Pubitemid 30225180)
47. Kuo CJ, Farnebo F, Yu EY et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl Acad. Sci. USA 98(8), 4605-4610 (2001). (Pubitemid 32295023)
48. Zhang Z, Zou W, Wang J et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol. Ther. 11(4), 553-562 (2005). (Pubitemid 40353113)
49. Sako A, Kitayama J, Koyama H et al. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 64(10), 3624-3628 (2004). (Pubitemid 38657941)
50. Hoshida T, Sunamura M, Duda DG et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble Flt-1 vascular endothelial growth factor receptor. Pancreas 25(2), 111-121 (2002). (Pubitemid 34815906)
51. Oba M, Vachutinsky Y, Miyata K et al. Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble Flt-1. Mol. Pharm. 7(2), 501-509 (2010).
52. Mahendra G, Kumar S, Isayeva T et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 12(1), 26-34 (2005). (Pubitemid 39665240)
53. Takei Y, Mizukami H, Saga Y et al. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/ Flt-1 using adeno-associated virus serotype 1-derived vector. Int. J. Cancer 120(2), 278-284 (2007). (Pubitemid 44956836)
54. Sallinen H, Anttila M, Narvainen J et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther. 17(2), 278-284 (2009).
55. Mahasreshti PJ, Navarro JG, Kataram M et al. Adenovirus-mediated soluble Flt-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. 7(7), 2057-2066 (2001). (Pubitemid 32994845)
56. Mahasreshti PJ, Kataram M, Wang MH et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res. 9(7), 2701-2710 (2003). (Pubitemid 36842116)
57. Liu JR, Li J, Su C, Huang BH, Luo SK. Soluble fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Bioch. Bioph. Sin. 39(7), 499-506 (2007). (Pubitemid 47117599)
58. Gao ZN, Wei YQ, Yang PS et al. Combined effects of soluble vascular endothelial growth factor receptor Flt-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. Oral Oncol. 43(5), 477-483 (2007).
59. Bertin S, Mohsen-Kanson T, Baque P et al. Tumor microenvironment modifications induced by soluble VEGF receptor expression in a rat liver metastasis model. Cancer Lett. 298(2), 264-272 (2010).
60. Hasumi Y, Mizukami H, Urabe M et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 62(7), 2019-2023 (2002). (Pubitemid 34408446)
61. Yin D, Jia T, Gong W et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int. J. Oncol. 33(2), 253-259 (2008).
62. Ye C, Feng C, Wang S et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 145(2), 817-822 (2004). (Pubitemid 38183825)
63. Hu M, Yang JL, Teng H et al. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer 8, 306 (2008).
64. Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a Phase II study. J. Clin. Oncol. 27(18), 3027-3035 (2009).
65. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
66. Duda DG, Willett CG, Ancukiewicz M et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15(6), 577-583 (2010).
67. Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary Phase II study. J. Clin. Oncol. 27(18), 3020-3026 (2009).
68. Hornig C, Behn T, Bartsch W, Yayon A, Weich HA. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J. Immunol. Methods 226(1-2), 169-177 (1999). (Pubitemid 29336541)